The global anti-obesity medication market size is expected to reach USD 77.24 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 31.66% from 2024 to 2030. The market is experiencing significant growth driven by the increasing prevalence of obesity, leading to increased demand for effective treatments. The market's expansion is supported by technological advancements and initiatives by both market players and governments.

The market players are actively pursuing strategic initiatives to expand their service reach through partnerships, mergers, acquisitions, and collaborations. These initiatives are aimed at driving market share growth. For instance, in November 2023, Novo Nordisk's investment in expanding production facilities in Chartres, France, signals confidence in the market's potential. The investment, totaling over USD 2.32 billion, will boost capacity for chronic disease treatments, potentially including weight management medications. In addition, governments and healthcare organizations prioritize obesity prevention and treatment, collaborative efforts are shaping regulatory frameworks and fostering innovation. This highlights the market's collective effort. For instance, in June 2023, the UK launched a USD 50.50 million pilot to broaden access to overweight drugs such as Semaglutide (Wegovy) beyond hospital environments, aligning with the government's comprehensive approach to addressing overweight.

Moreover, social media influence and forged prescriptions indicate non-diabetic usage for weight loss, prompting ANSM (Agence nationale de sécurité du médicament et des produits de santé) to emphasize Ozempic's intended use solely for diabetes treatment. However, in November 2023, Novo Nordisk's investment in expanding production facilities in Chartres, France, signals confidence in the market's potential. The investment, totaling overUSD 2.32 billion, will boost capacity for chronic disease treatments, potentially including anti-obesity medications. Despite regulatory challenges, such investments indicate optimism for the future of the anti-obesity medication market in France, suggesting a positive trajectory in the projected period.

Gather more insights about the market drivers, restrains and growth of the Anti-obesity Medication Market

Anti-obesity Medication Market Report Highlights

• By products, the approved segment accounted for the largest market share in 2023. It is expected to grow at a lucrative CAGR over the forecast period, owing to the accessibility of therapeutically effective weight management drugs

• Based on mechanism of action, the peripherally acting anti-obesity drugs segment accounted for the largest revenue share in 2023. The ability of these drugs to enhance the absorption of nutrients and reduce the feeling of hunger is anticipated to bode well for the segment’s growth.

• Retail pharmacies dominated the distribution channel segment in 2023, owing to the convenient access to medications for consumers, often located in easily accessible locations within communities

• North America dominated the market for anti-obesity medication in 2023, due to the region's high prevalence of obesity and supportive government policies

• Asia Pacific is anticipated to exhibit the fastest CAGR from 2024 to 2030, due to rising obesity and governmental initiatives across countries like China, Japan, and India. The rising investment in research by pharmaceutical companies is also expected to contribute to this growth.

Anti-obesity Medication Market Segmentation

Grand View Research has segmented the global anti-obesity medication market based on product, mechanism of action, distribution channel, and region:

Anti-obesity Medication Product Outlook (Revenue, USD Million, 2018 - 2030)

• Approved

o Bupropion-naltrexone (Contrave)

o Liraglutide (Orlistat)

o Orlistat

o Xenical

o Alli

o Phentermine-topiramate (Qsymia)

o Semaglutide (Wegovy)

o Setmelanotide (Imcivree)

o Tirzepatide (Zepbound)

• Off-label

o Semaglutide (Xenical Alli)

o Liraglutide (Semaglutide (Wegovy))

o Dulaglutide (Trulicity)

o Topiramate (Dulaglutide (Trulicity))

o Others

Anti-obesity Medication Mechanism of Action Outlook (Revenue, USD Million, 2018 - 2030)

• Peripherally Acting Drugs

• Centrally Acting Drugs

Anti-obesity Medication Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Retail Pharmacies

• Hospital Pharmacies

• Others

Anti-obesity Medication Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o UK

o Spain

o France

o Italy

o Sweden

o Denmark

o Norway

• Asia Pacific

o Japan

o China

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

o Kuwait

List of Key Players in the Anti-Obesity Medication Market

• Novo Nordisk A/S

• GSK plc

• Novartis AG

• VIVUS LLC

• Currax Pharmaceuticals LLC

• Boehringer Ingelheim International GmbH

• Rhythm Pharmaceuticals, Inc.

• Gelesis

Order a free sample PDF of the Anti-obesity Medication Market Intelligence Study, published by Grand View Research.